Roth, G. A. et al. Global burden of cardiovascular diseases and risk factors, 1990–2019 update from the GBD 2019 study. J. Am. Coll. Cardiol. 76, 2982–3021 (2020).
Google Scholar
Yusuf, S. et al. Modifiable risk factors, cardiovascular disease, and mortality in 155,722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet 395, 795–808 (2020).
Google Scholar
The Global Cardiovascular Risk Consortium. Global effect of modifiable risk factors on cardiovascular disease and mortality. N. Engl. J. Med. 389, 1273–1285 (2023).
Google Scholar
Yusuf, S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364, 937–952 (2004).
Google Scholar
Lewington, S. et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903–1913 (2002).
Google Scholar
Cholesterol Treatment Trialists’ Consortium. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670–1681 (2010).
Google Scholar
Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362, 1527–1535 (2003).
Google Scholar
Marcus, M. E. et al. Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data. Lancet Glob. Health 10, e369–e379 (2022).
Google Scholar
Nelson, A. J. et al. Use of lipid, blood pressure, and glucose-lowering pharmacotherapy in patients with type 2 diabetes and atherosclerotic cardiovascular disease. JAMA Netw. Open 5, e2148030 (2022).
Google Scholar
Yusuf, S. et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 378, 1231–1243 (2011).
Google Scholar
Secondary prevention of noncommunicable diseases in low- and middle-income countries through community-based and health service interventions: World Health Organization–Wellcome Trust meeting report, 1–3 August 2001. World Health Organization (2002).
Joseph, P. et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet 398, 1133–1146 (2021).
Google Scholar
Castellano, J. M. Polypill strategy in secondary cardiovascular prevention. N. Engl. J. Med. (2022).
Bahiru, E. et al. Fixed‐dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. Cochrane Database Syst. Rev. (2017).
Cates, et al. Fixed‐dose combination therapy for the prevention of cardiovascular disease. Cochrane Database Syst. Rev. CD009868 (2014).
Zamorano, J. et al. Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial. Curr. Med. Res. Opin. 27, 821–833 (2011).
Google Scholar
Neutel, J. M. et al. The use of a single‐pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo‐controlled, multicenter study. J. Clin. Hypertens. 11, 22–30 (2009).
Google Scholar
Castellano, J. M. et al. A polypill strategy to improve adherence results from the FOCUS project. J. Am. Coll. Cardiol. 64, 2071–2082 (2014).
Google Scholar
Selak, V. et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. Br. Med. J. 348, g3318 (2014).
Google Scholar
Patel, A. et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur. J. Prev. Cardiol. 22, 920–930 (2014).
Google Scholar
Malekzadeh, F. et al. A pilot double‐blind randomised placebo‐controlled trial of the effects of fixed‐dose combination therapy (‘polypill’) on cardiovascular risk factors. Int. J. Clin. Pr. 64, 1220–1227 (2010).
Google Scholar
Park, J.-S. et al. Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong). Drug Des. Dev. Ther. 10, 2599–2609 (2016).
Google Scholar
PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (‘polypill’) in people with raised cardiovascular risk. PLoS ONE 6, e19857 (2011).
Google Scholar
Soliman, E. Z. et al. A polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. Trials (2011).
The Indian Polycap Study (TIPS). Effects of a polypill (polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 373, 1341–1351 (2009).
Grimm, R. et al. Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial. Vasc. Health Risk Manag. 6, 261–271 (2010).
Google Scholar
Thom, S. et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 310, 918–929 (2013).
Google Scholar
Wald, D. S., Morris, J. K. & Wald, N. J. Randomized polypill crossover trial in people aged 50 and over. PLoS ONE 7, e41297 (2012).
Google Scholar
Kim, S.-H. et al. Blood pressure and cholesterol-lowering efficacy of a fixed-dose combination with irbesartan and atorvastatin in patients with hypertension and hypercholesterolemia: a randomized, double-blind, factorial, multicenter phase III study. Clin. Ther. 38, 2171–2184 (2016).
Google Scholar
Oh, G. C. et al. Efficacy and safety of fixed-dose combination therapy with telmisartan and rosuvastatin in Korean patients with hypertension and dyslipidemia: TELSTA-YU (TELmisartan-rosuvaSTAtin from YUhan), a multicenter, randomized, 4-arm, double-blind, placebo-controlled, phase III study. Clin. Ther. 40, 676–691.e1 (2018).
Google Scholar
Cho, K. I. et al. Efficacy and safety of a fixed-dose combination of candesartan and rosuvastatin on blood pressure and cholesterol in patients with hypertension and hypercholesterolemia: a multicenter, randomized, double-blind, parallel phase III clinical study. Clin. Ther. 41, 1508–1521 (2019).
Google Scholar
Muñoz, D. et al. Polypill for cardiovascular disease prevention in an underserved population. N. Engl. J. Med. 381, 1114–1123 (2019).
Google Scholar
Roshandel, G. et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet 394, 672–683 (2019).
Google Scholar
Chung, S. et al. Effect of FIXed-dose combination of ARb and statin on adherence and risk factor control: the randomized FIXAR study. Cardiol. J. 29, 815–823 (2022).
Google Scholar
Mariani, J. et al. Multicap to improve adherence after acute coronary syndromes: results of a randomized controlled clinical trial. Ther. Adv. Cardiovasc. Dis. 14, 1753944720912071 (2020).
Google Scholar
Choi, J. et al. Central blood pressure lowering effect of telmisartan‐rosuvastatin single‐pill combination in hypertensive patients combined with dyslipidemia: a pilot study. J. Clin. Hypertens. 23, 1664–1674 (2021).
Google Scholar
González-Juanatey, J. R. et al. Pharmacodynamic study of the cardiovascular polypill. Is there any interaction among the monocomponents? Rev. Esp. Cardiol. Engl. Ed. 74, 51–58 (2021).
Google Scholar
Yusuf, S. et al. Polypill with or without aspirin in persons without cardiovascular disease. N. Engl. J. Med. 3, 216–228 (2021).
Google Scholar
Merat, S. et al. Polypill for prevention of cardiovascular diseases with focus on non-alcoholic steatohepatitis: the PolyIran-Liver trial. Eur. Heart J. 21, 2023–2033 (2022).
Google Scholar
Kim, W. et al. A randomized, double‐blind clinical trial to evaluate the efficacy and safety of a fixed‐dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension. J. Clin. Hypertens. 22, 261–269 (2020).
Google Scholar
Zhu, J. Z. et al. Medication use for cardiovascular disease prevention in 40 low- and middle-income countries. J. Am. Coll. Cardiol. 81, 620–622 (2023).
Google Scholar
Yusuf, S. et al. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N. Engl. J. Med. 374, 2032–2043 (2016).
Google Scholar
Jahangiri, R. et al. Cost-effectiveness of fixed-dose combination pill (polypill) in primary and secondary prevention of cardiovascular disease: a systematic literature review. PLoS ONE 17, e0271908 (2022).
Google Scholar
Lamy, A. et al. The cost implications of a polypill for primary prevention in the TIPS-3 trial. Eur. Hear. J. Qual. Care Clin. Outcomes 8, 899–908 (2021).
Google Scholar
Abimbola, S. & Liu, H. Adoption and scale-up of the cardiovascular polypill: a realist institutional analysis. Health Policy Plan. 1, 15–27 (2023).
Google Scholar
Huffman, M. D., Xavier, D. & Perel, P. Uses of polypills for cardiovascular disease and evidence to date. Lancet 389, 1055–1065 (2017).
Google Scholar
Huffman, M. D., Salam, A. & Patel, A. Implementation strategies for cardiovascular polypills. JAMA 322, 2279–2280 (2019).
Google Scholar
Huffman, M. D. & Yusuf, S. Polypills essential medicines for cardiovascular disease secondary prevention? J. Am. Coll. Cardiol. 63, 1368–1370 (2014).
Google Scholar
Webster, R. et al. An electronic decision support‐based complex intervention to improve management of cardiovascular risk in primary health care: a cluster randomised trial (INTEGRATE). Med J. Aust. 214, 420–427 (2021).
Google Scholar
Rao, S. et al. Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: a systematic review and meta-analysis of randomized controlled trials. Prog. Cardiovasc. Dis. 73, 48–55 (2022).
Google Scholar
Selak, V. et al. Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials. Heart 105, 42 (2019).
Google Scholar
Abushouk, A. I. et al. Fixed-dose combination (polypill) for cardiovascular disease prevention: a meta-analysis. Am. J. Prev. Med. 63, 440–449 (2022).
Google Scholar
United States Preventive Services Task Forceet al. Aspirin use to prevent cardiovascular disease. JAMA 327, 1577–1584 (2022).
Google Scholar
Guyatt, G. H. et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Br. Med. J. 336, 924–926 (2008).
Google Scholar
Agarwal, A. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases: a systematic review update. (PROSPERO, 2021).
Higgins, J. P. T. et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3. www.training.cochrane.org/handbook (Cochrane, 2011).
Sterne, J. A. C. et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Br. Med. J. 366, l4898 (2019).
Google Scholar
Egger, M., Smith, G. D., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. Br. Med. J. 315, 629 (1997).
Google Scholar
link